Shari Sapuan (United Kingdom)

St George's, University of London Paediatric Infectious Diseases Research Group

Dr Shari Sapuan is a general paediatrician in training with a specialty interest in paediatric infectious diseases. She recently spent a considerable length of time out of her training as a research fellow with the Central Paediatric and Neonatal Infection and St George’s Vaccine Institute in St George’s University of London, where she developed further interest in congenital and maternal infection, particularly on CMV which will be the focus of her PhD thesis.

Author Of 1 Presentation

Conference Calendar

COMPARISON OF HUMAN CYTOMEGALOVIRUS (HCMV)-ENZYME-LINKED IMMUNE ABSORBENT SPOT (ELISPOT) AND CMV-QUANTIFERON CELL-MEDIATED IMMUNE ASSAY SERIAL MEASUREMENTS, IN HCMV-SEROPOSITIVE PREGNANT WOMEN IN SOUTH LONDON, ENGLAND

Date

Wed, 11.05.2022

Session Time

10:00 - 11:00

Session Type

Oral Presentations Session

Session Name

0260 - ORAL PRESENTATION SESSION 02: Neonatal (ID 49)

Room

DIMITRIS MITROPOULOS HALL

Presenter

Shari Sapuan (United Kingdom)

Lecture Time

10:42 - 10:52

Abstract

Abstract

Backgrounds:

HCMV-specific cell-mediated immunity (CMI) is essential in the control of viral replication to prevent end-organ HCMV disease. HCMV-specific interferon gamma release assays, such as HCMV-ELISPOT and HCMV-QuantiFERON, have been used to measure HCMV-specific CMI. In pregnant women, the role of HCMV-specific CMI in controlling viral replication and transmission to the foetus have not been fully investigated. We aimed to perform serial HCMV-ELISPOT and HCMV-QuantiFERON measurements in HCMV-seropositive women during pregnancy.

Methods

HCMV-seropositive pregnant women receiving antenatal care at a tertiary hospital in London (UK) were enrolled. Blood samples were collected at three time-points in pregnancy and a fourth time-point after delivery, and HCMV-ELISPOT and HCMV-QuantiFERON assays were performed on these samples. HCMV-ELISPOT was recorded as responsive or non-responsive, as a spot count, and as specific spot counts to IE-1 and pp65 antigens. HCMV-QuantiFERON was recorded as positive or negative.

Results:

From 67 HCMV-seropositive pregnant women, 105 blood samples were tested with both assays. All women had a responsive HCMV-ELISPOT result on at least one time-point, and 70% (47/67) of women had a positive HCMV-QuantiFERON result on at least one time-point. The two assays showed no overall agreement (Cohen’s Kappa 0.032), although the overall mean HCMV-ELISPOT spot counts to IE-1 and pp65 antigens were higher when HCMV-QuantiFERON was positive than when it was negative (Figure 1).

Conclusions/Learning Points:

In this cohort, the HCMV-ELISPOT assay was more likely than the HCMV-QuantiFERON assay to detect HCMV-specific CMI in HCMV-seropositive pregnant women. This may have implications for optimal CMI monitoring in this important population.

Hide